Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:15pm, Thursday, 04'th Jan 2024
PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 14'th Dec 2023
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
04:15pm, Tuesday, 21'st Nov 2023
PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
09:02am, Wednesday, 15'th Nov 2023
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
04:01pm, Tuesday, 14'th Nov 2023
PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.
Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate diff
PALO ALTO, Calif. , Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Acade
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
06:00am, Wednesday, 11'th Oct 2023
PALO ALTO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06:00am, Friday, 08'th Sep 2023
PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
11:44am, Wednesday, 16'th Aug 2023
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Should You Buy Kodiak Sciences (KOD) Ahead of Earnings?
10:09am, Monday, 14'th Aug 2023
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
08:39am, Monday, 14'th Aug 2023
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Kodiak (KOD) Down as Late-Stage DME Studies Fail
10:53am, Tuesday, 25'th Jul 2023
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.
Kodiak Sciences discontinues development of eye disorder therapeutic; shares plummet
01:59pm, Monday, 24'th Jul 2023
Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye disorders. The company's decision comes as its Phase
